Estren behaves as a weak estrogen rather than a nongenomic selective activator in the mouse uterus

Endocrinology. 2006 May;147(5):2203-14. doi: 10.1210/en.2005-1292. Epub 2006 Feb 9.

Abstract

A proposed membrane-mediated mechanism of rapid nongenomic response to estrogen has been the intense focus of recent research. Estren, a synthetic steroid, is reported to act selectively through a rapid membrane-mediated pathway, rather than through the classical nuclear estrogen receptor (ER)-mediated pathway, to maintain bone density in ovariectomized mice without uterotropic effects. To evaluate the mechanism and physiological effects of estren, we studied responses in adult ovariectomized mice. In a 3-d uterine bioassay, we found that 300 microg estren significantly increased uterine weight; in comparison, a more maximal response was seen with 1 mug estradiol (E2). The estren response was partly ERalpha independent, because ERalpha knockout (alphaERKO) uteri also exhibited a more moderate weight increase. Estren induced epithelial cell proliferation in wild-type, but not alphaERKO, mice, indicating ERalpha dependence of the epithelial growth response. Examination of estren-regulated uterine genes by microarray indicated that early (2 h) changes in gene expression are similar to the early responses to E2. These gene responses are ERalpha dependent, because they are not seen in alphaERKO mice. Later estren-induced changes in gene expression (24 h) are blunted compared with those seen 24 h after E2. In contrast to early genes, these later estren responses are independent of ERalpha, because the alphaERKO shows a similar response to estren at 24 h. We found that E2 or estren treatments lead to depletion of ERalpha in the uterine cytosol fraction and accumulation in the nuclear fraction within 30-60 min, consistent with the ability of estren to regulate genes through a nuclear ERalpha rather than a nongenomic mechanism. Interestingly, estren, but not E2, induces accumulation of androgen receptor (AR) in the nuclear fraction of both wild-type and alphaERKO samples, suggesting that AR might be involved in the later ERalpha-independent genomic responses to estren. In conclusion, our studies suggest that estren is weakly estrogenic in the mouse uterus and might induce nuclear ERalpha- and AR-mediated responses. Given its activity in our uterine model, the use of estren as a bone-selective clinical compound needs to be reconsidered.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • Base Sequence
  • Biological Assay
  • Blotting, Western
  • Bone Density
  • Bromodeoxyuridine / pharmacology
  • Cell Membrane / metabolism
  • Cell Nucleus / metabolism
  • Cytoplasm / metabolism
  • DNA Primers / chemistry
  • Estradiol / metabolism
  • Estrenes / metabolism
  • Estrenes / pharmacology*
  • Estrogen Receptor alpha / metabolism*
  • Estrogens / metabolism*
  • Female
  • Gene Expression Regulation
  • Immunohistochemistry
  • Lipid Metabolism
  • Mice
  • Mice, Knockout
  • Molecular Sequence Data
  • Oligonucleotide Array Sequence Analysis
  • Ovariectomy
  • Receptors, Androgen / metabolism*
  • Receptors, Estrogen / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Time Factors
  • Uterus / metabolism*

Substances

  • 4-estren-3,17-diol
  • DNA Primers
  • Estrenes
  • Estrogen Receptor alpha
  • Estrogens
  • Receptors, Androgen
  • Receptors, Estrogen
  • Estradiol
  • Bromodeoxyuridine